ACETYLCHOLINE RECEPTOR MODULATING ANTIBODY

Code
900.0130
Name
ACETYLCHOLINE RECEPTOR MODULATING ANTIBODY
Category
None
Department
Send-Out
Start Date
Expiration Date
Synonyms
AChR Modulating Ab; Myasthenia Gravis Ab
CPT Codes
83519
Site
SBMF
Reference Test
44510
ATLAS Test Code

ACET REC MOD AB

Specimen Information

Type

Gold, SST

Volume

0.5 ml

Transport Info

Centrifuge and transfer serum to a separate plastic tube Refrigerated

Fasting Required?
False
Patient Instructions

Reference Range

Negative: 0-20% modulation Indeterminate: 21-25% modulation Positive: Equal to or greater than 26% modulation

Methodology

Semi-Quantitative Radioreceptor Assay

Clinical Significance

Approximately 85-90% of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair AChR binding to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15% of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Back

Patients & Visitors

Make a First Appointment Maternity Pre-Registration Make a Donation Recognize a Sarah Bush Lincoln Employee